共 50 条
- [41] Impact of immunogenicity on 2-year clinical outcomes in patients with moderate-to-severe Crohn's disease treated with subcutaneous infliximab: A post hoc analysis of the Phase 3 LIBERTY-CD study JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1254 - I1256
- [42] Covariates Influencing the Exposure-Response Relationship for Certolizumab Pegol During the Induction and Maintenances Phases in Patients with Crohn's Disease AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S262 - S263
- [43] Relationship Between Protocol Specified Corticosteroid Tapering Regimens and Achieving Outcome Measures in Patients With Moderate-Severe Ulcerative Colitis and Crohn's Disease AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S448 - S448
- [44] Correlation between trough levels of risankizumab and clinical and biological remission in patients with moderate to severe Crohn's disease: a retrospective multicenter study (RISE-CD) JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1730 - i1730
- [49] Rapid symptomatic improvement with subcutaneous infliximab induction treatment for patients with moderate-to-severe Crohn's disease: first results from the DIRECT-CD study JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1682 - I1683
- [50] Efficacy and Safety of Dose Adjustment and Delayed Response to Ustekinumab in Moderate - Severe Crohn's Disease Patients: Results from the IM-UNITI Maintenance Study AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S302 - S303